Evaluating the Right Modalities to Deliver Gene Therapy at Scale in Common Diseases

• Comparing gene therapy to small molecules and biologics in terms of tractability and therapeutic reach
• Investigating whether advanced modalities like AAV, mRNA, or LNPs can meet the demands of high-prevalence diseases
• Delving into use cases to understand where gene therapy may offer unique value or face limitations

Speakers:

Ralf Schmid

Chief Scientific Officer

CureSHANK